Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts

Abstract

The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods.

Genetic and Functional Evaluation of the Role of FOXO1 in Antituberculosis Drug-Induced Hepatotoxicity

“…Our research also has some limitations. (1) e rs4435111 and rs2755237 loci, which were found to be associated with susceptibility to ATDH, are both located in intron regions, and no functional SNPs with strong linkage disequilibrium with them were identified.…”

The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis

“…Owing to the forward steps made in treating and preventing TB, in 2019, it is estimated that there will be 9.96 million new TB cases and 1.41 million deaths in the world. Since 2007, TB has been ranked as one of the top ten causes of death in the world and ranked first among all infectious diseases (1). Although novel diagnostic methods, medications, and vaccination for TB have been trialed, the most recommended drugs for the first-line treatment of TB are still isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) with/without streptomycin.…”

Fabrication of an Electrochemical Aptasensor Composed of Multifunctional DNA Three-Way Junction on Au Microgap Electrode for Interferon Gamma Detection in Human Serum

“…According to the World Health Organization (WHO), in 2019 alone, 1.4 million people died from TB, and about 10 million people were infected with TB [ 3 , 4 ]. The number of people infected with TB is declining by about 2% per year, but the number of new patients is still increasing due to the growing population [ 5 ]. The most effective way to manage TB risk is to quickly diagnose active TB patients and provide appropriate treatment to prevent the spread of TB bacteria, thereby preventing the occurrence of new TB patients.…”